Managing psychotic symptoms in the older patient

Geriatrics and Aging

Volumn 10, Issue 4, 2007, Pages 241-245

  Rayner, Abi ^a  

^a Buller Medical Service   (New Zealand)

Author keywords

Antipsychotics; Behavioural disturbance; Dementia; Older adult; Psychotic symptoms

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLONAZEPAM; DONEPEZIL; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; HALOPERIDOL; LORAZEPAM; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TRAZODONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZOLPIDEM TARTRATE;

BEHAVIOR DISORDER; CEREBROVASCULAR ACCIDENT; COGNITION; DEATH; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DRUG RESPONSE; HALLUCINATION; HUMAN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

EID: 34248150572     PISSN: 14888408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Rayner, A. Recognition of psychotic symptoms among older adults. Geriatrics Aging 2007;10:174-8.
2. Arunpongpaisal S, Ahmed I, Aqeel N, et al. Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database Syst Rev 2003,CD004162.
3. McKeith, IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006,9:417-23.
4. Burns A, O'Brien J, Auriacombe S, et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006;20:732-55.
5. Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry 2001;35:776-81.
6. Cervilla JA, Prince M, Joels S, et al. Does depression predict cognitive outcome 9 to 12 years later? Evidence from a prospective study of elderly hypertensives. Psychol Med 2000;30:1017-23.
7. Galvin JE, Powlishta KK, Wilkins K, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol 2005;62:758-65.
8. Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry 2002;10:125-8.
9. Rubin EH, Kinscherf DA, Grant EA, et al. The influence of major depression on clinical and psychometric assessment of senile dementia of the Alzheimer type. Am J Psychiatry 1991;148:1164-71.
10. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006;CD003491.
11. Schneider LS, Olin JT. Efficacy of acute treatment for geriatric depression. Int Psychogeriatr 1995;7 Suppl:7-25.
12. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000;9:29-34.
13. Holtzer R, Tang MX, Devanand DP, et al. Psychopathological features in Alzheimer's disease: course andrelationship with cognitive status. J Am Geriatr Soc 2003;31:953-60.
14. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 1989;25:39-48.
15. Leroi I, Voulgari A, Breitner JC, et al. The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry 2003;11:83-91.
16. Rosen HJ, Narvaez JM, Hallam B, et al. Neuropsychological and functional measures of severity in Alzheimer disease, frontotemporal dementia, and semantic dementia. Alzheimer Dis Assoc Disord 2004;18:202-7.
17. Mendez MF, Perryman KM. Neuropsychiatric features of frontotemporal dementia: evaluation of consensus criteria and review. J Neuropsychiatry Clin Neurosci 2002;14:424-9.
18. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment J Clin Psychiatry 1987;48 Suppl:9-15.
19. Callahan CM, Boustani MA, Unverzagt FW, et aL Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. J Am Med. Assoc 2006;295:2148-57.
20. Tibaldi V, Aimonino N, Ponzetto M, et al. A randomized controlled trial of a home hospital intervention for frail elderly demented patients: behavioral disturbances and caregiver's stress. Arch Gerontol Geriatr Suppl 2004;431-6.
21. Alexopoulos GS, Jeste DV, Chung H, et al. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad Med 2005;6-22.
22. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. J Am Med Assoc 2005;293:396-608.
23. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999;7:70-6.
24. Schneider LS, Tariot FN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38.
25. Katz IR, Rupnow M, Kozma C, et al. Risperidone and falls in ambulatory nursing home residents with dementia and psychosis or agitation: secondary analysis of a double-blind, placebo-controlled trial. Am J Geriatr Psychiatry 2004;12:499-508.
26. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc 2005;294:1934-43.
27. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210.
28. Wang PS, Schneeweiss S, Avom J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353;2335-41.
29. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005;17:617-29.
30. Center for Drug Evaluation and Research. Deaths with antipsychotics in elderly patients with behavioral disturbances. FDA Public Health Advisory. 2005. Ref Type: Electronic Citation.
31. Schneider LS, Ismail MS, Dagerman K, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophr Bull 2003;29:57-72.
32. Karlawish J. Alzheimer's disease - clinical trials and the logic of clinical purpose. N Engl J Med 2006;355:1604-6.
33. Katz IR, Jeste D, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double blind trial. J.Clin.Psychiatry 1999;60:107-15.
34. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of ripseridone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-43.
35. Kurz A, Schwalen SS, Schmitt A. Effects of risperidone on behavioral and psychological symptoms associated wtih dementia in clinical practice. Int Psychogeriatr 2005;17:605-16.
36. Mintzer J, Greenspan A, Caers I, et al. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry 2006;14:280-91.
37. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:115-26.
38. Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006;14:767-76.
39. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000;22:1068-84.
40. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002;159:460-5.
41. Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006;14:605-12.
42. Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;6757-63.
43. McLeod PJ, Huang AR, Tamblyn RM, et al. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ 1997;156:385-91.
44. Rayner AV, O'Brien JG, Schoenbachler B. Behavior disorders of dementia: recognition and treatment. Am Fam Physician 2006;73:647-52.
45. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen.Psychiatry 2000;37:968-76.
46. Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int.J Geriatr Psychiatry 2001;16 Suppl:S62-S70.
47. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2001;CD002852.
48. Martin BK, Frangakis CE, Rosenberg PB, et al. Design of Depression in Alzheimer's Disease Study-2. Am J Geriatr Psychiatry 2006;14:920-30.
49. Weiner MF, Martin-Cook K, Foster BM, et al. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry 2000;61:487-92.
50. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-76.
51. Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004;161:532-8.
52. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6.
53. Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67:57-63.
54. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J Am Med Assoc 2004;291:317-24.
55. Olin JT, Fox LS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001;9:400-5.
56. Tariot PN, Raman R, Jakimpvich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 2005;13:942-9.